Prompted by reports challenging the validity of low-positive Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) results generated by the APTIMA Combo 2 Assay (Gen-Probe, Incorporated) and by a CDC recommendation to confirm Ng-or Ct-positive screens by using an alternative amplification target, we report a comparison of this means of confirmation with an inhouse algorithm of repeat testing. Primary clinical specimens yielding Ng-or Ct-specific luminescent values between 100,000 and 1,000,000 were repeat tested in duplicate. A subset of specimens was forwarded for confirmatory assays (Gen-Probe) individualized for alternative Ng positive Ct screens yielded a positive result in fewer specimens (n = 97; 63.4%) than when commercial confirmatory testing was employed (n = 124; 81.0%). However, confirmation of additional Ct screens using an alternative target did not translate into significant differences in calculated overall Ct-positive screen rates (7.39% using repeat testing versus 7.52% via confirmatory assay; P = 0.53). Furthermore, utilization of the confirmatory assay raised positive predictive value only 1.8% over that of repeat testing. Molecular confirmatory testing did not significantly enhance the reliability of Ct-or Ng-specific nucleic acid amplification testing in this metropolitan setting when compared to repeat testing.
INTRODUCTION 1 4 antibody or competitive probe) or by assaying original/new clinical material with a different test 24
that uses a different antigen, phenotype, or target and a different format. 25 26 Schachter et al. [26] cited a number of valid limitations inherent to this paradigm and 27 demonstrated in low-and moderate-prevalence disease populations that C. trachomatis 28 confirmatory testing is unnecessary. In this report, we summarize our experiences with C. Table 2 ) when compared to all C. trachomatis 100 low-positive screens encountered in the audit (Table 1 ; P = 0.10). In similar fashion, no 101 Table 2 ) when compared to all N. gonorrhoeae low-positive 104 screens (Table 1 ; P = 0.44). Furthermore, no significant difference was observed in the 105 frequency at which low-positive C. trachomatis and N. gonorrhoeae screens generated a 106 negative result upon duplicate repeat testing (P > 0.26; Table 2 (Table 3) when 113 compared to duplicate repeat testing (Table 2) (Table 3 ). This change was unlikely a byproduct of specimen source as only 5% of 199 specimens subjected to confirmatory testing in this study were urine specimens. occur at a rate (~1%) similar to the AC2 rate reported in this study and others [8, 32] Our data confirm and extend the findings of Schachter, Zanto, and colleagues [25, 34] to a 209 population of high gonorrhea and chlamydia prevalence. Limitations to adopting the CDC 210 follow-up testing recommendations include clinicians not routinely providing two specimens for 211 evaluation, the lack of feasibility in calling a patient back for specimen recollection, and the 212 prohibitive expense for some laboratories to either modify an existing molecular assay to target a 213 different nucleic acid sequence or validate a second NAAT [26] . Even when NAATs are utilized 214 as a means of confirmation, Schachter et al. [26] reported differences in performance 215 characteristics of these assays, deficiencies in result reproducibility for a given specimen using 216 the same testing modality, and potential differences in sensitivity related to heterologous 217 specimen collection media/transport devices. As a result, additional generated data may be 218 difficult to interpret, especially when considering the extremely high rates of sensitivity and 219 specificity already inherent to these screening assays [2, 5, 10, 11, 16] Extrapolation of data generated from evaluation of a subset of low-positive Chlamydia trachomatis and Neisseria gonorrhoeae screens using duplicate repeat testing or APTIMA confirmatory testing to data generated from an eighteenmonth audit of APTIMA Combo 2 performance.
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